{"entity": "researcher", "timestamp": "2026-07-20T23:05:41.020Z", "family": "Wikstr\u00f6m", "given": "Pernilla", "initials": "P", "orcid": "0000-0002-6347-1999", "affiliations": ["Department of Medical Biosciences, Pathology, Ume\u00e5 University, Sweden."], "links": {"self": {"href": "https://publications.scilifelab.se/researcher/66e1e640e83948a4a3f8a1ddd49bd953.json"}, "display": {"href": "https://publications.scilifelab.se/researcher/66e1e640e83948a4a3f8a1ddd49bd953"}}, "publications": [{"entity": "publication", "iuid": "fe4fbf54443842c687e997679feba32e", "links": {"self": {"href": "https://publications.scilifelab.se/publication/fe4fbf54443842c687e997679feba32e.json"}, "display": {"href": "https://publications.scilifelab.se/publication/fe4fbf54443842c687e997679feba32e"}}, "title": "Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models.", "authors": [{"family": "Classon", "given": "Johanna", "initials": "J", "orcid": "0000-0003-0392-7605", "researcher": {"href": "https://publications.scilifelab.se/researcher/641cf9db52e64f9fb8eee60a977a88be.json"}}, {"family": "Stenudd", "given": "Moa", "initials": "M"}, {"family": "Zamboni", "given": "Margherita", "initials": "M"}, {"family": "Alkass", "given": "Kanar", "initials": "K"}, {"family": "Eriksson", "given": "Carl-Johan", "initials": "CJ"}, {"family": "Pedersen", "given": "Lars", "initials": "L"}, {"family": "Sch\u00f6rling", "given": "Alrik", "initials": "A"}, {"family": "Thoss", "given": "Anna", "initials": "A"}, {"family": "Bergh", "given": "Anders", "initials": "A"}, {"family": "Wikstr\u00f6m", "given": "Pernilla", "initials": "P", "orcid": "0000-0002-6347-1999", "researcher": {"href": "https://publications.scilifelab.se/researcher/66e1e640e83948a4a3f8a1ddd49bd953.json"}}, {"family": "Adami", "given": "Hans-Olov", "initials": "HO"}, {"family": "S\u00f8rensen", "given": "Henrik Toft", "initials": "HT"}, {"family": "Druid", "given": "Henrik", "initials": "H"}, {"family": "Fris\u00e9n", "given": "Jonas", "initials": "J", "orcid": "0000-0001-5819-458X", "researcher": {"href": "https://publications.scilifelab.se/researcher/23064ee2ac9b4c2fb1eb94e61f92148e.json"}}], "type": "journal article", "published": "2025-11-00", "journal": {"title": "Mol Oncol", "issn": "1878-0261", "volume": "19", "issue": "11", "pages": "3035-3059", "issn-l": "1574-7891"}, "abstract": "Metastatic prostate cancer is incurable, and new therapeutic targets and drugs are urgently needed. Viral infections are associated with several cancer types, but a link between viruses and prostate oncogenesis has not been established. Only recently, an association between human cytomegalovirus (CMV) seropositivity and increased risk of prostate cancer mortality was demonstrated. Here, we show that CMV infection is common in the normal prostate epithelium and in prostate tumor tissue, with 70-92% of tumors being infected. Additionally, we report that commonly studied prostate cancer cell lines are CMV infected. Loss-of-function experiments demonstrate that CMV promotes cell survival, proliferation, and androgen receptor signaling, identifying it as a therapeutic target in castration-sensitive and castration-resistant prostate cancer. Several anti-CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models both in vitro and in vivo. We conclude that CMV is common in prostate cancer, promotes core prostate cancer cell programs, and can be inhibited by well-tolerated drugs. These findings motivate investigation into potential clinical benefits of CMV inhibition in the treatment of prostate cancer.", "doi": "10.1002/1878-0261.70073", "pmid": "40493023", "labels": {"Bioinformatics Support for Computational Resources": "Service"}, "xrefs": [{"db": "pmc", "key": "PMC12591316"}], "notes": [], "created": "2025-11-28T10:39:38.461Z", "modified": "2025-11-28T10:39:38.586Z"}, {"entity": "publication", "iuid": "d5c0c16b13b14f5e88c23efe7344bee1", "links": {"self": {"href": "https://publications.scilifelab.se/publication/d5c0c16b13b14f5e88c23efe7344bee1.json"}, "display": {"href": "https://publications.scilifelab.se/publication/d5c0c16b13b14f5e88c23efe7344bee1"}}, "title": "Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.", "authors": [{"family": "Thysell", "given": "Elin", "initials": "E"}, {"family": "K\u00f6hn", "given": "Linda", "initials": "L"}, {"family": "Semenas", "given": "Julius", "initials": "J", "orcid": "0000-0001-5394-7239", "researcher": {"href": "https://publications.scilifelab.se/researcher/e0402a104066426dbeb5108ac120a46f.json"}}, {"family": "J\u00e4remo", "given": "Helena", "initials": "H"}, {"family": "Freyhult", "given": "Eva", "initials": "E"}, {"family": "Lundholm", "given": "Marie", "initials": "M"}, {"family": "Thellenberg Karlsson", "given": "Camilla", "initials": "C"}, {"family": "Damber", "given": "Jan-Erik", "initials": "JE"}, {"family": "Widmark", "given": "Anders", "initials": "A"}, {"family": "Crnalic", "given": "Sead", "initials": "S"}, {"family": "Josefsson", "given": "Andreas", "initials": "A"}, {"family": "Wel\u00e9n", "given": "Karin", "initials": "K"}, {"family": "Nilsson", "given": "Rolf J A", "initials": "RJA"}, {"family": "Bergh", "given": "Anders", "initials": "A"}, {"family": "Wikstr\u00f6m", "given": "Pernilla", "initials": "P", "orcid": "0000-0002-6347-1999", "researcher": {"href": "https://publications.scilifelab.se/researcher/66e1e640e83948a4a3f8a1ddd49bd953.json"}}], "type": "journal article", "published": "2022-02-00", "journal": {"title": "Mol Oncol", "issn": "1878-0261", "issn-l": "1574-7891", "volume": "16", "issue": "4", "pages": "846-859"}, "abstract": "To improve treatment of metastatic prostate cancer, the biology of metastases needs to be understood. We recently described three subtypes of prostate cancer bone metastases (MetA-C), based on differential gene expression. The aim of this study was to verify the clinical relevance of these subtypes and to explore their biology and relations to genetic drivers. Freshly-frozen metastasis samples were obtained as hormone-naive (n = 17), short-term castrated (n = 21), or castration-resistant (n = 65) from a total of 67 patients. Previously published sequencing data from 573 metastasis samples were also analyzed. Through transcriptome profiling and sample classification based on a set of predefined MetA-C-differentiating genes, we found that most metastases were heterogeneous for the MetA-C subtypes. Overall, MetA was the most common subtype, while MetB was significantly enriched in castration-resistant samples and in liver metastases, and consistently associated with poor prognosis. By gene set enrichment analysis, the phenotype of MetA was described by high androgen response, protein secretion and adipogenesis, MetB by high cell cycle activity and DNA repair, and MetC by epithelial-to-mesenchymal transition and inflammation. The MetB subtype demonstrated single nucleotide variants of RB transcriptional corepressor 1 (RB1) and loss of 21 genes at chromosome 13, including RB1, but provided independent prognostic value to those genetic aberrations. In conclusion, a distinct set of gene transcripts can be used to classify prostate cancer metastases into the subtypes MetA-C. The MetA-C subtypes show diverse biology, organ tropism, and prognosis. The MetA-C classification may be used independently, or in combination with genetic markers, primarily to identify MetB patients in need of complementary therapy to conventional androgen receptor-targeting treatments.", "doi": "10.1002/1878-0261.13158", "pmid": "34889043", "labels": {"Bioinformatics Support, Infrastructure and Training": "Collaborative", "Bioinformatics Support and Infrastructure": "Collaborative", "Clinical Genomics Ume\u00e5": "Service", "Bioinformatics (NBIS)": "Collaborative", "Clinical Genomics": "Service"}, "xrefs": [{"db": "pmc", "key": "PMC8847984"}], "notes": [], "created": "2022-01-11T07:51:15.811Z", "modified": "2022-12-05T11:19:52.667Z"}]}